1-3 of 3
Yehudit Fox
Close
Sort by
Journal Articles

Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation

Meghan C. Thompson, Catherine C. Coombs, Lindsey E. Roeker, Jeffrey L. Jensen, Nirav N. Shah, Thomas Luo, Krish Patel, Neil Bailey, Bita Fakhri, Toby A. Eyre, Paola Ghione, Joanna M. Rhodes, Andrew D. Zelenetz, Justin Taylor, Maria Lia Palomba, Kendall Meyer, Danielle Rao, Yehudit Fox, Julia H. Aronson, Sarah Court, Omar Abdel-Wahab, Anthony R. Mato
Journal: Blood
Blood (2022) 140 (Supplement 1): 9885–9888.
https://doi.org/10.1182/blood-2022-159133
Published: 2022
Journal Articles

Outcomes of Chronic Lymphocytic Leukemia and Richter Transformation Following Discontinuation of Non-Covalent Bruton's Tyrosine Kinase Inhibitors

Meghan C. Thompson, Catherine C. Coombs, Lindsey E. Roeker, John M. Pagel, Jeffrey L. Jensen, Kristen E. Battiato, Yehudit Fox, Kendall Meyer, Neil Bailey, Joanna M Rhodes, Paola Ghione, Bita Fakhri, Toby A. Eyre, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 2629.
https://doi.org/10.1182/blood-2021-148592
Published: 2021
Journal Articles

A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach

Lindsey E. Roeker, Lori A. Leslie, Jake D. Soumerai, Victoria Falco, Gail Panton, Andrew D. Zelenetz, Lorenzo Falchi, Jae H Park, Camila Pena-Velasquez, Sonia Lebowitz, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, David J. Straus, Yehudit Fox, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Hari P. Miskin, Peter Sportelli, Anthony R. Mato
Journal: Blood
Blood (2021) 138 (Supplement 1): 395.
https://doi.org/10.1182/blood-2021-146999
Published: 2021